---
layout: ../../layouts/Article.astro
title: "BPC-157: A Complete Evidence-Based Guide"
description: "A science-backed guide to BPC-157 (Body Protection Compound-157) covering mechanisms of action, research-backed benefits, dosage protocols, reconstitution, side effects, and legal status."
image: /images/articles/bpc-157.webp
date: 2026-02-13
category: "Peptide Guides"
tags: ["BPC-157", "body protection compound", "peptides", "gut healing", "tendon repair", "neuroprotection", "research peptides"]
author: "PeptideRundown Team"
---

# BPC-157: A Complete Evidence-Based Guide

**BPC-157** is one of the most widely discussed peptides in the research and biohacking communities, and for good reason. With over two decades of published preclinical research suggesting benefits ranging from gut healing to tendon repair, it's attracted significant interest from athletes, clinicians, and researchers alike.

The science behind this synthetic 15-amino-acid peptide is both promising and complex. Derived from a protein in human gastric juice, BPC-157 has shown remarkable healing properties across multiple tissue types in animal studies. But what does the current evidence actually tell us, and what are the real-world implications for human use?

This guide breaks down everything we know about BPC-157: what it is, how it works, what it may do, and what we still don't know. Most importantly, we'll examine the research with appropriate skepticism while highlighting both the potential and the limitations of this fascinating compound.

The most commonly referenced human-equivalent dose, extrapolated from animal studies, falls in the range of **250-500 mcg** once or twice daily via subcutaneous injection. However, no large-scale human clinical trials exist as of early 2026, and the FDA has restricted compounding pharmacy access in the United States.

## What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a protein found in human gastric juice. Its complete amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

The "body protection compound" designation comes from its parent protein, which naturally occurs in the stomach and appears to play a role in maintaining gastrointestinal lining integrity. BPC-157 represents a partial sequence of this larger protein, isolated and studied for its concentrated biological activity.

Unlike many peptides that degrade rapidly in gastric acid, BPC-157 demonstrates remarkable stability in the gastrointestinal tract. This unique property makes it a candidate for both injectable and oral administration in research settings, setting it apart from most other therapeutic peptides.

The peptide was first characterized by researchers at the University of Zagreb in Croatia, led by Professor Predrag Sikiric. His laboratory has published the majority of existing literature on BPC-157 since the early 1990s, contributing over 100 peer-reviewed papers on the compound [1].

| Property | Detail |
|---|---|
| Type | Synthetic pentadecapeptide (15 amino acids) |
| Molecular Weight | ~1,419 Da |
| Origin | Partial sequence of human gastric juice protein BPC |
| Primary Research | Preclinical (animal models, in vitro) |
| Human Trials | Limited; no completed large-scale RCTs as of early 2026 |
| FDA Status | Not approved for human use |

## How BPC-157 Works: Mechanisms of Action

BPC-157's mechanisms are complex and not fully elucidated, but research has identified several key pathways through which it exerts its effects. These mechanisms work synergistically to promote healing and tissue protection across multiple organ systems.

### Angiogenesis and Blood Vessel Formation

One of BPC-157's most well-documented effects is the promotion of angiogenesis, the formation of new blood vessels. Studies demonstrate that it upregulates vascular endothelial growth factor (VEGF) expression and promotes the VEGF-VEGFR2 signaling pathway [2, 3]. This angiogenic effect is believed to be a central mechanism behind BPC-157's observed benefits in tendon, ligament, muscle, and gut tissue healing.

The peptide's ability to stimulate new blood vessel formation isn't just academic—it translates to real improvements in tissue oxygenation and nutrient delivery. This enhanced vascular supply accelerates healing processes and may explain why BPC-157 shows efficacy across such diverse tissue types.

### Nitric Oxide System Modulation

BPC-157 interacts with the nitric oxide system in a sophisticated way that sets it apart from simple agonists or antagonists. Research suggests it can counteract both NO excess and NO deficiency, acting as a modulator rather than pushing the system in one direction [4].

This modulatory effect is particularly significant because dysregulated NO signaling is implicated in conditions ranging from gastrointestinal ulcers to cardiovascular dysfunction. BPC-157's ability to normalize NO activity, rather than simply increase or decrease it, may contribute to its broad therapeutic potential.

### Growth Factor Upregulation

Beyond VEGF, BPC-157 influences several growth factors crucial to tissue repair. It upregulates epidermal growth factor (EGF), which is involved in mucosal healing, hepatocyte growth factor (HGF), relevant to liver and tissue repair, and fibroblast growth factor (FGF), critical for connective tissue maintenance and repair [5].

This broad growth factor engagement may explain why BPC-157 appears to accelerate healing across multiple tissue types. Rather than targeting a single pathway, it seems to orchestrate a coordinated healing response involving multiple cellular signaling systems.

### Cellular Signaling Pathways

BPC-157 activates the FAK-paxillin signaling pathway, which plays a key role in cell migration, adhesion, and tissue remodeling. These are essential processes in wound healing and tendon repair [6]. Additionally, the peptide appears to interact with dopaminergic and GABAergic systems, showing protective effects against dopamine-related neurotoxicity and potential anxiolytic-like effects in animal models [7, 8].

## What BPC-157 Can Do: Research-Backed Benefits

The evidence base for BPC-157 is substantial but comes with an important caveat: the vast majority of research is preclinical, conducted in rodent models or in vitro. While this body of evidence is extensive and consistent, human clinical data remains very limited.

### Gastrointestinal Healing

As a compound derived from gastric juice, BPC-157's strongest evidence base involves the gastrointestinal tract. It has demonstrated protective and healing effects across multiple GI conditions in animal studies, including accelerated healing of gastric, duodenal, and colonic ulcers caused by NSAIDs, alcohol, stress, and surgery [1, 9].

In inflammatory bowel disease models, BPC-157 reduced inflammation, promoted mucosal healing, and improved clinical scores comparable to standard treatments [10]. The peptide also accelerated surgical gut healing and reduced adhesion formation in anastomosis studies [11]. Perhaps most impressively, it showed protective effects against acid reflux-induced esophageal damage [9].

### Tendon and Ligament Repair

The tendon-healing effects of BPC-157 have generated intense interest in athletic and sports medicine communities. In Achilles tendon studies, the peptide significantly accelerated healing of transected tendons in rats, with improved biomechanical properties and more organized collagen fiber formation [12]. Similar acceleration of healing was demonstrated in medial collateral ligament injury models [13].

These effects appear mediated through increased collagen production, tendon fibroblast proliferation, FAK-paxillin pathway activation, and enhanced angiogenesis [6, 12]. The combination of improved blood supply and optimized collagen formation creates an ideal environment for tendon repair.

### Muscle and Bone Healing

BPC-157 has shown positive effects on muscle healing in several injury models, including accelerated recovery from crush injuries, improved healing of surgically transected muscles, and protective effects against muscle wasting associated with systemic conditions [14]. Limited but promising research suggests the peptide may also accelerate fracture healing, with studies in rabbit models showing improved bone callus formation and faster radiographic healing following segmental bone defects [15].

### Neuroprotection

BPC-157 has demonstrated several neuroprotective properties in animal models that extend far beyond tissue healing. In traumatic brain injury studies, it reduced brain edema, improved behavioral outcomes, and promoted neuronal survival [16]. For peripheral nerve injury, the peptide accelerated nerve regeneration and improved functional recovery following sciatic nerve crush [17].

Perhaps most intriguingly, BPC-157 showed dopaminergic protective effects, counteracting neurotoxic effects in models relevant to Parkinson's-like pathology [7]. It may also exert antidepressant-like effects through interactions with the serotonin system [8].

### Cardiovascular and Systemic Effects

BPC-157's cardiovascular effects demonstrate its modulatory nature rather than simple stimulation or inhibition. It counteracted both hypertensive and hypotensive states in animal models, suggesting a blood pressure normalizing effect [4]. The peptide also demonstrated anti-arrhythmic properties, counteracting digitalis-induced arrhythmias [18].

Additional systemic effects include hepatoprotective properties against alcohol-induced liver injury and NSAID-induced liver toxicity [19]. One of BPC-157's most consistently demonstrated effects is protection against the damaging effects of NSAIDs, including protection of gastric mucosa, intestinal lining, liver, and brain [1, 9].

## BPC-157 Dosage: How Much to Take

Most protocols reference dosages of **250-500 mcg** once or twice daily via subcutaneous injection, typically for 4-8 weeks. These doses are extrapolated from animal studies using allometric scaling, which provides a starting point but isn't perfect for cross-species translation.

The most commonly discussed human-equivalent dose falls in the range of 200-500 mcg per administration, given 1-2 times daily. This corresponds to approximately 2.5-10 mcg/kg when calculated on a body-weight basis. Duration protocols typically run 4-8 weeks, though there's no established evidence-based cycling protocol.

| Parameter | Range |
|-----------|-------|
| Typical dose | 200-500 mcg per administration |
| Frequency | 1-2 times daily |
| Duration | Typically 4-8 weeks |
| Body-weight equivalent | ~2.5-10 mcg/kg (extrapolated from rodent studies) |

### Routes of Administration

Subcutaneous injection represents the most common route for systemic effects or localized tissue repair. Many protocols recommend administering near the site of injury when targeting specific areas, though animal studies have demonstrated systemic effects even with non-local administration routes.

Oral administration is discussed primarily for gastrointestinal applications, taking advantage of BPC-157's unusual stability in gastric acid [1]. Intramuscular and intraperitoneal routes are used in animal research but less commonly discussed in human contexts.

Some practitioners discuss cycling protocols of 4-6 weeks on followed by a break, but this approach is based on clinical judgment rather than controlled trial data. There's no established evidence-based cycling protocol in the literature.

## How to Reconstitute BPC-157 (Step-by-Step)

BPC-157 is typically supplied as a lyophilized powder in a sealed vial that must be reconstituted with sterile solvent before use. The most common solvent is bacteriostatic water, which contains 0.9% benzyl alcohol as a preservative.

Need help with the math? Use our free [Peptide Reconstitution Calculator](https://peptidearc.com/tools/reconstitution) on PeptideArc to get exact measurements instantly. For a detailed walkthrough, see our full [reconstitution guide](/articles/how-to-reconstitute-peptides).

The reconstitution process involves gathering materials including the BPC-157 vial, bacteriostatic water, insulin syringe (typically 1 mL), and alcohol swabs. Clean both vial tops with alcohol swabs and allow to dry completely.

Draw bacteriostatic water into the syringe using standard concentration ratios: 5 mg vial plus 2 mL BAC water creates 2,500 mcg/mL concentration, where each 0.1 mL equals 250 mcg. Alternatively, 5 mg vial plus 1 mL BAC water creates 5,000 mcg/mL concentration, where each 0.1 mL equals 500 mcg.

Inject the water slowly into the BPC-157 vial, aiming the stream against the glass wall rather than directly onto the powder. Swirl gently until fully dissolved—avoid vigorous shaking. Store the reconstituted solution in the refrigerator at 2-8°C and don't freeze once reconstituted.

| State | Storage | Shelf Life |
|---|---|---|
| Lyophilized (unreconstituted) | Refrigerated or frozen | Months to years |
| Reconstituted (BAC water) | Refrigerated (2-8°C) | 3-4 weeks |

Avoid repeated freeze-thaw cycles, direct sunlight, and temperatures above 8°C for extended periods.

## BPC-157 Side Effects and Safety Profile

BPC-157 has demonstrated a remarkably favorable safety profile in preclinical studies, with no lethal dose established even at extremely high doses and no mortality observed in acute toxicity testing [1]. No organ toxicity has been observed at therapeutic or supratherapeutic doses in subchronic studies, and no mutagenic or carcinogenic effects have been reported in the existing literature.

In the limited clinical reports and community use, reported side effects are generally mild and infrequent. These include mild nausea (more common with oral administration), rare instances of dizziness or lightheadedness, injection site reactions such as redness and mild discomfort, infrequent headache, and rare fatigue or lethargy.

**Important safety considerations exist despite the favorable profile.** Limited human data means no large-scale human clinical trials have been conducted, so definitive safety claims can't be made for human use. The peptide's blood vessel promoting properties represent a double-edged sword—individuals with active cancer should exercise extreme caution [2].

Long-term effects remain unknown since most studies examine acute or short-term use only. Source quality varies significantly in the unregulated peptide market, where contamination and mislabeling are real concerns. Effects on NO, dopaminergic, and other systems suggest potential interactions with medications.

Anyone with active malignancies or taking prescription medications should consult a physician before considering BPC-157.

## Is BPC-157 Legal? Current Regulatory Status

BPC-157's legal status in the United States has become more restrictive in recent years. The peptide is not an FDA-approved drug and has never completed the approval process for any indication. Between 2022-2024, the FDA issued warning letters to companies marketing BPC-157 for human use, particularly those making therapeutic claims.

In late 2023 and into 2024-2025, the FDA placed BPC-157 on its list of substances that can't be used in compounding under section 503A and 503B, citing insufficient safety and efficacy data. The peptide remains available as a research chemical for in vitro research and non-human use, while personal use exists in a gray area—purchasing research peptides isn't explicitly illegal, but self-administration falls outside FDA-sanctioned use.

International status varies significantly. Canada offers availability through some compounding pharmacies under a different regulatory framework than the US. The European Union hasn't approved BPC-157 as a pharmaceutical product, though it's available in some countries as a research compound. Australia classifies it under the TGA with prescription-level regulation applying.

**For athletes**: BPC-157 is not currently on the WADA Prohibited List as of 2025, but athletes should verify status regularly since this can change.

Regulatory status can change rapidly. Always verify current regulations in your jurisdiction before purchasing or using any peptide.

## Frequently Asked Questions

### Is BPC-157 natural?

BPC-157 represents a partial answer to this question. It's a synthetic peptide, but its amino acid sequence derives from a naturally occurring protein found in human gastric juice. The specific 15-amino-acid sequence doesn't exist as a standalone molecule in the body, making it both natural in origin and synthetic in production.

### How quickly does BPC-157 work?

Animal studies have documented measurable effects on tissue healing within days, with significant improvements typically observed over 1-4 weeks. Anecdotal human reports are broadly consistent with this timeline, though individual responses vary considerably based on the condition being addressed and individual factors.

### Can BPC-157 be taken orally?

Yes, and this represents one of BPC-157's unique properties among peptides. It demonstrates stability in gastric acid and has shown efficacy via oral administration in animal studies, particularly for gastrointestinal applications [1]. For non-GI targets, subcutaneous injection is more commonly discussed and may offer better bioavailability.

### Does BPC-157 need to be injected near the injury site?

This remains a subject of debate among practitioners and researchers. Some protocols recommend local (perilesional) injection near injured tissue, theorizing that higher local concentrations may enhance healing effects. However, animal studies have demonstrated systemic effects even with non-local administration routes, including oral and intraperitoneal [1]. The optimal approach likely depends on the specific application and desired outcomes.

### Can BPC-157 be stacked with other peptides?

BPC-157 is frequently discussed in combination with [TB-500 (Thymosin Beta-4 fragment)](/articles/tb-500-complete-guide) for tissue healing applications. While both peptides promote healing through overlapping but distinct mechanisms—BPC-157 focusing on angiogenesis and growth factor upregulation, TB-500 on cell migration and tissue remodeling—there are no controlled studies examining this combination in humans. The theoretical rationale is sound, but evidence remains anecdotal.

### Is BPC-157 safe for long-term use?

This question can't be answered definitively with current data. Existing safety information comes from relatively short-term animal studies, and the theoretical concern about angiogenesis is particularly relevant for long-term administration. The lack of chronic safety data in any species means long-term use involves unknown risks.

### Will BPC-157 show up on a drug test?

Standard workplace drug panels don't test for BPC-157 or other research peptides. Advanced peptide-specific testing, as may be used by some sports organizations, could potentially detect it. Athletes subject to testing should consult their sport's governing body and verify current testing protocols.

## What We Still Don't Know About BPC-157

Several important knowledge gaps remain in BPC-157 research that affect how we should interpret existing data and approach potential use. The concentration of research from a single research group (Sikiric et al., University of Zagreb) has produced the majority of studies, and independent replication would strengthen the evidence base significantly.

As of early 2026, no completed large-scale randomized controlled trials in humans exist. This represents the most significant limitation in translating animal research to human applications. Dose translation uncertainty also persists, as extrapolating doses from rodent models to humans using allometric scaling is imperfect and may not account for species-specific differences in metabolism and receptor sensitivity.

Long-term safety profiles in any species aren't well characterized, and the chronic effects of BPC-157 administration remain unknown. Mechanism specificity represents another gap—while we understand several pathways BPC-157 affects, the relative contribution of each pathway to observed effects remains unclear.

These gaps don't invalidate the existing research, which is substantial and generally well-conducted. However, they underscore the need for caution and intellectual honesty when discussing BPC-157's potential and limitations.

## Summary

BPC-157 is a synthetic peptide with an extensive preclinical evidence base suggesting benefits for tissue healing, gastrointestinal protection, neuroprotection, and more. Its mechanisms involve angiogenesis, nitric oxide modulation, growth factor upregulation, and interactions with multiple neurotransmitter systems working synergistically to promote healing and tissue protection.

The preclinical safety profile is favorable, with no lethal dose established in rodent studies and no significant organ toxicity observed. However, the lack of large-scale human clinical trials means definitive efficacy and safety claims can't be made for human use. The theoretical concern regarding angiogenesis in individuals with active cancer deserves particular attention.

As of 2025-2026, BPC-157 faces increasing regulatory restrictions in the United States, particularly regarding compounding pharmacy access. It remains available as a research chemical, though this status may continue evolving. International availability varies significantly by country and regulatory framework.

For anyone considering BPC-157, consultation with a knowledgeable healthcare provider is strongly recommended. The peptide represents a fascinating example of how natural compounds can inspire synthetic therapeutics, but the translation from promising animal research to human application requires careful consideration of both potential benefits and unknown risks.

New to peptides? Start with our [beginner's guide to peptide therapy](/articles/what-are-peptides-beginners-guide). You can also learn about [peptide side effects](/articles/peptide-side-effects-what-to-know) and [how to store peptides properly](/articles/how-to-store-peptides).

## References

- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. *Curr Pharm Des.* 2014;20(7):1126-1135. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23829361/)

- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. *J Mol Med.* 2017;95(3):323-333. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27900448/)

- Tkalcevic VI, Cuzic S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds. *Eur J Pharmacol.* 2007;570(1-3):212-221. [PubMed](https://pubmed.ncbi.nlm.nih.gov/17628536/)

- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. *Front Pharmacol.* 2018;9:1408.

- Vukojevic J, Siroglavic M, Kasnik K, et al. Rat inferior caval vein (ICV) ligature and particular pentadecapeptide BPC 157 therapy. *Vasc Pharmacol.* 2018;106:46-57. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29501668/)

- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. *J Appl Physiol.* 2011;110(3):774-780. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21030672/)

- Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease. *Inflammopharmacology.* 2006;14(5-6):214-221. [PubMed](https://pubmed.ncbi.nlm.nih.gov/17091493/)

- Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. *Curr Pharm Des.* 2018;24(18):1990-2001. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29756564/)

- Sikiric P et al. *Life Sci.* 1994;54(5):PL63-68. [PubMed](https://pubmed.ncbi.nlm.nih.gov/8163129/)

- Cesarec V, Becejac T, Misic M, et al. Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy. *Eur J Pharmacol.* 2013;701(1-3):203-212. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23220707/)

- Skorjanec S, Dolovski Z, Kocman I, et al. Therapy for unhealed gastrocutaneous fistulas in rats. *Dig Dis Sci.* 2009;54(12):2602-2611. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19117128/)

- Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat. *J Orthop Res.* 2006;24(5):1109-1117. [PubMed](https://pubmed.ncbi.nlm.nih.gov/16609979/)

- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 improves ligament healing in the rat. *J Orthop Res.* 2010;28(9):1155-1161. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20225319/)

- Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury. *Surg Today.* 2008;38(8):716-725. [PubMed](https://pubmed.ncbi.nlm.nih.gov/18668316/)

- Sebecic B, Nikolic V, Sikiric P, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on healing of segmental bone defect in rabbits. *Bone.* 1999;24(3):195-202. [PubMed](https://pubmed.ncbi.nlm.nih.gov/10071910/)

- Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. *Regul Pept.* 2010;160(1-3):26-32. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19931579/)

- Gjurasin M, Miklic P, Zupancic B, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. *Regul Pept.* 2010;160(1-3):33-41. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19903499/)

- Barisic I, Balenovic D, Klicek R, et al. Mortal hyperkalemia disturbances in rats are NO-system related. *Regul Pept.* 2013;181:16-26. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23318498/)

- Ilic S, Brcic I, Mester M, et al. Over-dose insulin and stable gastric pentadecapeptide BPC 157. *J Physiol Pharmacol.* 2009;60 Suppl 7:107-114. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20388953/)

*Last updated: February 13, 2026*

*This article is maintained by the PeptideRundown Team and updated as new research becomes available. If you find an error or have a suggestion, [contact us](/contact).*

*PeptideRundown.com provides evidence-based educational content about peptides. We do not sell peptides, and we are not affiliated with any peptide supplier. Nothing on this site constitutes medical advice.*